Fig. 6: High Cyclin E and CDK5 expression can predict recurrence in all subtypes of salivary gland tumors. | Oncogenesis

Fig. 6: High Cyclin E and CDK5 expression can predict recurrence in all subtypes of salivary gland tumors.

From: LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers

Fig. 6: High Cyclin E and CDK5 expression can predict recurrence in all subtypes of salivary gland tumors.

A–D Kaplan–Meier plots for subtypes Aci, AdCC, SDC, and MEC, respectively, according to LMW-E, CDK5, or LMW-E/CDK5 expression. The expression of LMW-E and CDK5, individually and combined, were significantly associated with decreased time to recurrence in all the cohorts. p Values indicate comparison between survival curves, calculated using the log-rank (Mantel–Cox) test. E–H. Graph comparing median RFS without any biomarkers (black bars) to that when patient tumor samples are positive (H-score = 1) for LMW-E (blue bars), CDK5 (pink bars), or LMW-E /CDK5 (yellow bars) for each subtype.

Back to article page